| What Falling Estimates & Price Mean for Myriad Genetics (MYGN) - Tale of the Tape | |
| | |
|
One such stock that you may want to consider dropping is Myriad Genetics Inc. (MYGN), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in MYGN.
A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 13 estimates moving down in the past 30 days, compared to no upward revision. This trend has caused the consensus estimate to trend lower, going from $1.84 per share a month ago to its current level of $1.53 per share.
Also, for the current quarter, Myriad Genetics has seen 10 downward estimate revisions versus no revision in the opposite direction, dragging the consensus estimate down to 39 cents a share from 55 cents per share over the past 30 days.
The stock also has seen some pretty dismal trading lately, as the share price has dropped 11.1 % in the past month.
So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.
If you are still interested in the Medical-Biomedical/Generic industry, you may instead consider a better-ranked stock - Affymetrix Inc. (AFFX). The stock currently holds a Zacks Rank #1 (Strong Buy) and may be better selection at this time.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MYRIAD GENETICS (MYGN): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
|
|
| |
ProfilIndicateurs de MarchéVALEUR : Projets & res.Communiqués de PresseRapport annuelRISQUE : Profile actifsContactez la cie |
Myriad Genetics est une société basée aux Etats-Unis D'Amerique. Myriad Genetics est cotée aux Etats-Unis D'Amerique. Sa capitalisation boursière aujourd'hui est 1,7 milliards US$ (1,6 milliards €). La valeur de son action a atteint son plus bas niveau récent le 29 mai 1998 à 10,00 US$, et son plus haut niveau récent le 17 novembre 2000 à 94,06 US$. Myriad Genetics possède 68 090 000 actions en circulation. |